A Novel Bispecific T Cell Engager (UMG2BTCE) Targeting CD1a-CD3e Is Effective Against Cortical-Derived Acute Lymphoblastic Leukemia

被引：0
|
作者：
Riillo, Caterina [1 ]
Caracciolo, Daniele [1 ]
Grillone, Katia [1 ]
Polera, Nicoletta [1 ]
Juli, Giada [1 ]
Scionti, Francesca [2 ]
Ascrizzi, Serena [1 ]
Tuccillo, Franca Maria [3 ]
Bonelli, Patrizia [3 ]
Arbitrio, Mariamena [4 ]
Di Martino, Maria Teresa [1 ]
Tagliaferri, Pierosandro [1 ]
Tassone, Pierfrancesco [1 ,5 ]
机构：
[1] Magna Graecia Univ Catanzaro, Catanzaro, Italy
[2] Italian Natl Council CNR, IRIB, Messina, Italy
[3] Ist Nazl Tumori Fdn G Pascale, Naples, Italy
[4] IRIB CNR, Catanzaro, Italy
[5] Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Philadelphia, PA USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-153043
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2259
引用
收藏
页数：4
相关论文
共 50 条
  • [1] A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells
    Riillo, Caterina
    Caracciolo, Daniele
    Grillone, Katia
    Polera, Nicoletta
    Tuccillo, Franca Maria
    Bonelli, Patrizia
    Juli, Giada
    Ascrizzi, Serena
    Scionti, Francesca
    Arbitrio, Mariamena
    Lopreiato, Mariangela
    Siciliano, Maria Anna
    Sestito, Simona
    Talarico, Gabriella
    Galea, Eulalia
    Galati, Maria Concetta
    Pensabene, Licia
    Loprete, Giovanni
    Rossi, Marco
    Ballerini, Andrea
    Gentile, Massimo
    Britti, Domenico
    Di Martino, Maria Teresa
    Tagliaferri, Pierosandro
    Tassone, Pierfrancesco
    CANCERS, 2022, 14 (12)
  • [2] Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
    Wu, Jingjing
    Fu, Jiaping
    Zhang, Mingzhi
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [3] Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
    Jingjing Wu
    Jiaping Fu
    Mingzhi Zhang
    Delong Liu
    Journal of Hematology & Oncology, 8
  • [4] A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model
    Joshua F. Meckler
    Daniel J. Levis
    Daniel P. Vang
    Joseph M. Tuscano
    Cancer Immunology, Immunotherapy, 2023, 72 : 2939 - 2948
  • [5] A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model
    Meckler, Joshua F.
    Levis, Daniel J.
    Vang, Daniel P.
    Tuscano, Joseph M.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (09) : 2939 - 2948
  • [6] UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma
    Caracciolo, Daniele
    Polera, Nicoletta
    Belmonte, Beatrice
    Conforti, Francesco
    Signorelli, Stefania
    Gulino, Alessandro
    Staropoli, Nicoletta
    Tuccillo, Franca Maria
    Bonelli, Patrizia
    Juli, Giada
    Grillone, Katia
    Ascrizzi, Serena
    Cirillo, Maria
    Migale, Leonardo
    Ballerini, Andrea
    Pelizon, Cristina
    Di Martino, Maria Teresa
    Tagliaferri, Pierosandro
    Riillo, Caterina
    Tassone, Pierfrancesco
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (02) : 555 - 560
  • [7] Novel conditionally active bispecific HER2 x CD3 T cell engager targeting solid tumors
    Cugnetti, Ana Paula
    Liu, Haizhen
    McNeeley, Patricia
    Wheeler, Christina
    Lucas, Matthew
    Xing, Charles
    Joyner, Solmarie
    Johnson, Kyrie
    Woodard, Kathryn
    Zhou, Wei
    Chang, Cathy
    Frey, Gerhard
    Boyle, William J.
    Short, Jay M.
    CANCER RESEARCH, 2023, 83 (07)
  • [8] T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
    Feucht, Judith
    Kayser, Simone
    Gorodezki, David
    Hamieh, Mohamad
    Doring, Michaela
    Blaeschke, Franziska
    Schlegel, Patrick
    Bosmuller, Hans
    Quintanilla-Fend, Leticia
    Ebinger, Martin
    Lang, Peter
    Handgretinger, Rupert
    Feuchtinger, Tobias
    ONCOTARGET, 2016, 7 (47) : 76902 - 76919
  • [9] Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia
    Sisi Wang
    Lijun Peng
    Wenqian Xu
    Yuebo Zhou
    Ziyan Zhu
    Yushan Kong
    Stewart Leung
    Jin Wang
    Xiaoqiang Yan
    Jian-Qing Mi
    Frontiers of Medicine, 2022, 16 : 139 - 149
  • [10] Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia
    Wang, Sisi
    Peng, Lijun
    Xu, Wenqian
    Zhou, Yuebo
    Zhu, Ziyan
    Kong, Yushan
    Leung, Stewart
    Wang, Jin
    Yan, Xiaoqiang
    Mi, Jian-Qing
    FRONTIERS OF MEDICINE, 2022, 16 (01) : 139 - 149
12345